Theravance Biopharma amends 8-K to disclose consulting agreement with departing EVP & General Counsel

Theravance Biopharma, Inc.

Bradford Shafer, EVP & General Counsel, resigned effective Sep 30, 2021; consulting agreement signed same day.
Consulting term runs Sep 30 to Nov 30, 2021; up to 5 hours/week for transition support.
Restricted share units originally vesting Nov 20, 2021 and Feb 20, 2022 will both vest on Nov 20, 2021.
Agreement includes standard confidentiality, non-solicitation (12 months), and invention assignment provisions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bradford Shafer

EVP & General Counsel

TBPH · Theravance Biopharma, Inc.

Effective: 2021-09-30
Filed: October 5, 2021, 7:59 PM ET

the Company and Mr. Shafer entered into a consulting agreement to facilitate the transition of activities following Mr. Shafer’s departure

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.85

Bradford Shafer resigned as EVP & General Counsel at Theravance Biopharma, Inc..

Action: resigned
Role: EVP & General Counsel

Exact text from the filing

the Company and Mr. Shafer entered into a consulting agreement to facilitate the transition of activities following Mr. Shafer’s departure

View on SEC.gov

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-123200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.